Welcome to our dedicated page for Atricure SEC filings (Ticker: ATRC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AtriCure, Inc. (ATRC) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. AtriCure is a Nasdaq Global Market registrant whose common stock is listed under the symbol ATRC, and its filings offer detailed information on financial performance, capital structure, and material corporate events.
Investors can review Form 8-K current reports in which AtriCure discloses items such as preliminary and quarterly financial results, amendments to its Credit Agreement, and the creation of direct financial obligations. For example, recent 8-K filings describe an amendment to the company’s asset-based revolving credit facility with JPMorgan Chase Bank, N.A., including an extension of the term, a reduction in the overall interest rate, and changes to certain covenants. Other 8-Ks furnish press releases detailing revenue by product category and geography, non-GAAP metrics like adjusted EBITDA and adjusted loss per share, and commentary on operating trends.
Through its periodic reports and related exhibits, AtriCure outlines balance sheet data, income statement details, and non-GAAP reconciliations. These materials help readers understand how the company reports revenue from open ablation, minimally invasive ablation, pain management, and appendage management, as well as its research and development and selling, general, and administrative expenses. The filings also describe the structure and collateral of the ABL Facility, including the security interest in the assets of the borrowers and guarantees by material domestic subsidiaries.
On this page, Stock Titan enhances access to AtriCure’s filings with AI-powered summaries that explain the key points of lengthy documents such as 8-Ks and, when available, 10-Q and 10-K reports. Real-time updates from the SEC’s EDGAR system ensure that new filings appear promptly, while AI-generated highlights can help users quickly identify important changes in credit agreements, financial guidance, or operating results without reading every line of the original filing.
For those tracking ATRC, this filings hub is a central resource for analyzing the company’s disclosed financial condition, capital arrangements, and significant events as reported in its official SEC documents.
On this Form 4, AtriCure (ATRC) Chief Scientific Officer Vinayak S. Doraiswamy reported an open-market sale of 2,500 common shares on 08/05/2025 at $36.58 per share, yielding roughly $91 K in proceeds. After the transaction, he directly owns 71,872 shares, down about 3.4% from 74,372, leaving a stake worth ~$2.6 M at the sale price. No derivative trades were disclosed, and the filing cites no Rule 10b5-1 plan. Aside from this single sale, the document contains no financial results, guidance, or additional corporate events.
AtriCure, Inc. (ATRC) – Form 144 filing
- Proposed sale: 2,452 common shares (≈0.005% of the 49.7 million shares outstanding).
- Estimated value: US$90,307 based on market price at filing.
- Selling party: Not identified; shares held for the account of an insider who received them as a stock-award (compensation) on 05/20/2021.
- Broker: Fidelity Brokerage Services LLC.
- Planned trade date: on or after 08/06/2025; exchange: NASDAQ.
- No other ATRC shares have been sold by this person in the past three months.
The notice is procedural under Rule 144 and involves a de-minimis volume relative to total float. It has no dilution effect and signals only a routine insider liquidity event. Investors typically view such a small Form 144 filing as neutral and non-material to valuation or governance considerations.
On 30 Jul 2025 AtriCure, Inc. ("ATRC") filed a Form S-8 with the SEC to register 1,700,000 additional shares of common stock for issuance under its 2023 Stock Incentive Plan. Because the company is a large accelerated filer, the shares become eligible for grant immediately upon effectiveness.
The filing incorporates by reference the company’s 2024 Form 10-K, 2025 Form 10-Qs and a recent Form 8-K, and includes standard undertakings and indemnification language. Keating Muething & Klekamp PLL supplied the legal opinion, while Deloitte & Touche LLP provided the auditor’s consent. No new financial statements, pricing terms or selling shareholder information are presented.
The registration expands the equity pool used to attract, retain and motivate employees and directors; however, issuance of the newly registered shares could dilute existing shareholders when awards vest or are exercised.
AtriCure (ATRC) Q2-25 10-Q highlights: Revenue rose 17.1% YoY to $136.1 M, driven by 41% growth in Pain Management and 19% in Appendage Management; Minimally Invasive Ablation fell 34%. International sales advanced 23% (20% cc). Six-month revenue reached $259.8 M, +15.4% YoY.
Gross margin held at 74.5%. Operating loss narrowed to $6.2 M from $7.2 M; net loss improved to $6.2 M (-$0.13 EPS) vs. $8.0 M (-$0.17). YTD net loss nearly halved to $12.9 M. Cash flow from operations swung to +$10.6 M (vs. -$13.6 M). Cash & equivalents ended at $117.8 M; long-term ABL debt unchanged at $61.9 M, leaving $61.9 M in unused capacity.
R&D expense jumped 43% to $29.3 M, including a $5 M milestone for the pulsed-field ablation (PFA) Cooperation Agreement. SG&A rose 6.5% on headcount. Key milestones: FDA 510(k) clearances for AtriClip PRO-Mini and cryoICE cryoXT (launches 2H-25); completion of 6,500-patient LeAAPS stroke-prevention trial enrollment.
Risk factors: a Delaware suit from former SentreHEART holders seeks up to $260 M over PMA milestone; management deems loss not probable/estimable. Minimally invasive revenue weakness and flat margins bear monitoring.